Cardiovascular Health Effects of Flavanol Rich Chocolate

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01308892

Acronym

CHOC

Enrollment

Registered

2011-03-04

Start date

2011-01-31

Completion date

2011-06-30

Last updated

2011-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Dysfunction

Brief summary

In the CHOC study the investigators will examine the effect of chocolate flavanols on vascular function, inflammation, oxidative stress and markers of endothelial function. The effects of both acute consumption and prolonged consumption will be studied. The secondary objectives are to investigate if daily intake of chocolate flavanols for 4 weeks will improve the response to a high fat/high energy challenge.

Interventions

DIETARY_SUPPLEMENTHigh flavanol chocolate

chocolate high in flavanols

DIETARY_SUPPLEMENTLow flavanol chocolate

chocolate low in flavanols

DIETARY_SUPPLEMENTHigh fat challenge

Milkshake with 95g fat

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

MALE

Age

45 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Male * 45-70 years old * BMI between 25 and 32 kg/m2

Exclusion criteria

* Urine glucose concentrations outside normal ranges (\> 0,25 g/l) * Fasting blood glucose \< 7.0 mmol/L) * Systolic Bp \> 160 mmHg or diastolic Bp \> 100 mmHg * Blood Hb values below 8.4 mmol/L * Allergic to cow milk, dairy products or chocolate * Vegetarian * Tobacco smoker * Diagnosed with any long-term medical condition (e.g., diabetes, hemophilia, cardiovascular disease, anemia, gastrointestinal disease, renal failure)

Design outcomes

Primary

Measure	Time frame
Blood pressure	0, 4wk
FMD	0, 4wk
PWA	0, 4wk

Secondary

Measure	Time frame	Description
Blood pressure	0 and 2h	acute study part
FMD	0 and 2hrs	acute study part
leukocyte count and activation	0, 4wk	—
Leukocyte count and activation	0 and 2 hrs	acute study part
markers of inflammation and ED	0 and 2hrs	acute study part
PWA	0 and 2 hrs	acute study part
PBMC gene expression	0, 4wk	—
Markers of inflammation and ED	0, 4wk	—

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026